Background Due to the different infiltration abundance of immune cells in tumor, the efficacy
of immunotherapy varies widely among individuals. Recently, growing evidence suggested …

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the “L-group”
histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are …

Langerhans cell histiocytosis (LCH) is a complex disorder characterized by the clonal
proliferation of Langerhans cells, primarily affecting children and adolescents. This condition …

The aim of this study is to investigate the clinical potential of immune microenvironment in
peripheral blood for the severity and therapeutic efficacy of Langerhans cell histiocytosis …

Recent data suggest that programmed cell death-1 (PD-1) and programmed cell death
ligand-1 (PD-L1) are involved in the pathogenesis of Langerhans cell histiocytoma (LCH); …

The inflammation/immune response pathway is considered a key contributor to the
development of Langerhans cell histiocytosis (LCH) bone metastasis. However, the dynamic …

Erdheim-Chester disease (ECD) is a rare form of non-LCH characterized by excessive
accumulation of histiocytes in various tissues, leading to significant morbidity. The estimated …

Introduction Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm, encompassing
a diverse clinical spectrum ranging from localized bone or skin lesions to a multisystemic life …

Background: Cuproptosis induction is seen as a promising alternative for immunotherapies
and targeted therapies in breast cancer. The objective of this research was to examine the …

In this study, the immune microenvironment in Langerhans cell histiocytosis (LCH) was
characterized to determine if immune indices are predictive of severity. Serum samples from …